Liver toxicity of rosuvastatin therapy

World Journal of Gastroenterology

Volumn 13, Issue 8, 2007, Pages 1286-1288

  Famularo, Giuseppe ^a   Miele, Luca ^b   Minisola, Giovanni ^a   Grieco, Antonio ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Hepatitis; Liver; Rosuvastatin; Statins; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; RAMIPRIL; ROSUVASTATIN;

ACUTE HEART INFARCTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ANGIOPLASTY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CORONARY STENT; DISEASE DURATION; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG UPTAKE; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ECHOGRAPHY; HUMAN; LABORATORY TEST; LIVER BIOPSY; LIVER CELL; LIVER TOXICITY; MALE; PHYSICAL EXAMINATION; RISK ASSESSMENT; TREATMENT DURATION;

EID: 34247175882     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i8.1286     Document Type: Article

References (12)

1. de Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004; 24: 584-591
2. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1: 495-505
3. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
4. Ramos Ramos JC, Sanz Moreno J, Calvo Carrasco, L, Garcia Diaz Jde D. Clopidogrel-induced hepatotoxicity. Med Clin (Barc) 2003; 120: 156-157
5. Duran Quintana JA, Jimenez Saenz M, Montero AR, Gutierrez MH. Clopidogrel probably induced hepatic toxicity. Med Clin (Barc) 2002; 119: 37
6. Willens HJ. Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. Am J Ther 2000; 7: 317-318
7. Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S, Gardiner G. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 2003; 127: 1493-1497
8. Fry SW, Seeff LB. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am 1995; 24: 875-905
9. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-970
10. Tornio A, Pasanen MK, Laitila J, Neuvonen PJ, Backman JT. Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 2005; 97: 104-108
11. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111: 3051-3057
12. Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa K, Nakano M, Koike M. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002; 30: 1158-1163